P. Papaldo

发表

HER2 Protein and Gene Variation between Primary and Metastatic Breast Cancer: Significance and Impact on Patient Care

M. Mottolese, F. Cognetti, A. Fabi, 2011, Clinical Cancer Research.

Aromatase inhibitors in post-menopausal metastatic breast carcinoma

M. Pino, M. Milella, F. Cognetti, 2007, Expert opinion on investigational drugs.

New aromatase inhibitors as second‐line endocrine therapy in postmenopausal patients with metastatic breast carcinoma

M. Mottolese, S. Di Cosimo, M. Milella, 2005, Cancer.

Effect of Filgrastim on Serum Lactate Dehydrogenase and Alkaline Phosphatase Values in Early Breast Cancer Patients

S. Di Cosimo, F. Cognetti, A. Fabi, 2004, Cancer investigation.

Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis.

F. Cognetti, A. Fabi, P. Carlini, 2007, Bone.

Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide.

S. Di Cosimo, A. Fabi, P. Carlini, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Zoledronic-Acid-Induced Circulating Level Modifications of Angiogenic Factors, Metalloproteinases and Proinflammatory Cytokines in Metastatic Breast Cancer Patients

S. Di Cosimo, A. Alimonti, F. Cognetti, 2005, Oncology.

Ifosfamide given by continuous-intravenous infusion in association with vinorelbine in patients with anthracycline-resistant metastatic breast cancer: A phase I–II clinical trial

F. Cognetti, A. Fabi, S. Tomao, 1999, Cancer Chemotherapy and Pharmacology.

Clinical Evaluation of the Use of Exemestane as Further Hormonal Therapy after Nonsteroidal Aromatase Inhibitors in Postmenopausal Metastatic Breast Cancer Patients

S. Ricci, S. Di Cosimo, A. Alimonti, 2007, Cancer investigation.

HER 2 change between primary and metastatic breast cancer 1 HER 2 PROTEIN AND GENE VARIATION BETWEEN PRIMARY AND METASTATIC BREAST CANCER : SIGNIFICANCE AND IMPACT ON PATIENT CARE

M. Mottolese, F. Cognetti, A. Fabi, 2011 .

Predictive Biomarkers and Personalized Medicine HER 2 Protein and Gene Variation between Primary and Metastatic Breast Cancer : Significance and Impact on Patient Care

M. Mottolese, F. Cognetti, A. Fabi, 2011 .

Does granulocyte colony-stimulating factor worsen anemia in early breast cancer patients treated with epirubicin and cyclophosphamide?

A. Ceribelli, M. Mottolese, S. Di Cosimo, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Altered Expression of FAS System Is Related to Adverse Clinical Outcome in Stage I-II Breast Cancer Patients Treated with Adjuvant Anthracycline-Based Chemotherapy

M. Mottolese, F. Cognetti, P. Natali, 2004, Clinical Cancer Research.

Major bleedings in the comparisons between low-molecular weight heparin versus oral anticoagulant therapy for venous thromboembolism.

M. Mandalà, F. Cognetti, A. Fabi, 2007, Thrombosis Research.

Is recurrent venous thromboembolism after therapy reduced by low-molecular-weight heparin compared with oral anticoagulants?

M. Mandalà, F. Cognetti, A. Fabi, 2006, Chest.

Zoledronic Acid and Angiogenesis

F. Cognetti, A. Fabi, S. Tomao, 2007, Clinical Cancer Research.

Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial.

R. Demicheli, G. Altavilla, V. Adamo, 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Taxanes and gemcitabine doublets in the management of HER-2 negative metastatic breast cancer: towards optimization of association and schedule.

F. Cognetti, A. Fabi, P. Carlini, 2008, Anticancer research.

Acute myeloid leukaemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy

G. Ferretti, P. Papaldo, 2008, Breast Cancer Research and Treatment.

Lineage-specific hematopoietic growth factors.

F. Cognetti, G. Ferretti, P. Papaldo, 2006, The New England journal of medicine.

HER2 change between primary and metastatic breast cancer 1 HER2 PROTEIN AND GENE VARIATION BETWEEN PRIMARY AND METASTATIC BREAST CANCER: SIGNIFICANCE AND IMPACT ON PATIENT CARE

M. Mottolese, F. Cognetti, A. Fabi, 2011 .

Changes in HER2 overexpression between primary tumor and autologous metastases: Correlations with clinical and biological features

M. Mottolese, F. Cognetti, A. Fabi, 2008 .

HER2/neu expression and hormonal therapy in early breast cancer: can muddy waters become clear?

M. Mandalà, S. Di Cosimo, A. Alimonti, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Metronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: current status and future development.

M. Mencoboni, A. Del Conte, R. Addeo, 2016, Future oncology.

5-Fluorouracil, adriamycin, cyclophosphamide (FAC) vs. 5-fluorouracil, epirubicin, cyclophosphamide (FEC) in metastatic breast cancer.

P. Vici, L. di Lauro, E. Conti, 1989, Oncology.

Weekly paclitaxel plus capecitabine in advanced breast cancer patients: dose-finding trial of GOIRC and GOL.

F. di Costanzo, F. Mazzoni, F. Cognetti, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Can the addition of prophylactic filgrastim be considered cost effective in early breast cancer patients treated with epirubicin and cyclophosphamide?

G. Ferretti, P. Papaldo, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hormonal treatment of disseminated male breast cancer.

L. di Lauro, P. Papaldo, M. López, 1985, Oncology.

Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy: what is the appropriate use of filgrastim?

F. Cognetti, D. Giannarelli, E. Cortesi, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Granulocyte colony-stimulating factor-associated complications and increase in leukocyte number.

G. Ferretti, P. Papaldo, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Role of P53 and BCL-2 in high-risk breast cancer patients treated with adjuvant anthracycline-based chemotherapy

M. Mottolese, S. Buglioni, P. Vici, 2000, Journal of Cancer Research and Clinical Oncology.

Is there a benefit by the sequence anastrozole–formestane for postmenopausal metastatic breast cancer women?

S. Cosimo, F. Cognetti, A. Fabi, 2003, The Journal of Steroid Biochemistry and Molecular Biology.

Congenital ichthyosis and endodermal sinus tumor of the ovary in a ten-year-old child.

P. Papaldo, F. Sciarretta, M. López, 1983, Medical and pediatric oncology.

Assessment of PTEN and PI3K status in primary breast cancer and corresponding metastases: is it worthwhile?

M. Mottolese, F. Cognetti, A. Fabi, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nail disorders in a woman treated with ixabepilone for metastatic breast cancer.

A. Vecchione, A. Alimonti, F. Cognetti, 2005, Anticancer research.

Nanoparticle albumin-bound paclitaxel/liposomal-encapsulated doxorubicin in HER2-negative metastatic breast cancer patients.

G. Arpino, F. Cognetti, A. Fabi, 2020, Future oncology.

Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies.

M. Mottolese, S. Di Cosimo, F. Cognetti, 2008, Breast.

Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer

D. Amadori, L. Mariani, D. Crivellari, 2007, Breast Cancer Research and Treatment.

Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial

S. Barni, C. Boni, P. Bruzzi, 2015, The Lancet.

Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine.

L. Crinò, M. Mottolese, F. Cognetti, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and

L. Crinò, M. Mottolese, F. Cognetti, 2010 .

Lumpectomy and tamoxifen alone without additional radiotherapy for women 70 years of age or older with estrogen receptor-positive breast cancer

M. Mandalà, F. Cognetti, A. Fabi, 2005, Breast Cancer Research and Treatment.

HER2/neu role in breast cancer: from a prognostic foe to a predictive friend

F. Cognetti, A. Fabi, G. Ferretti, 2007, Current opinion in obstetrics & gynecology.

Docetaxel in Advanced Gastric Cancer Review of the Main Clinical Trials

S. Di Cosimo, A. Alimonti, F. Cognetti, 2003, Acta oncologica.

Oral idarubicin in non-Hodgkin's lymphomas

Massimo Lopez, P. Papaldo, L. Lauro, 1986, Investigational New Drugs.

Phase II trial with oral idarubicin in advanced breast cancer

Massimo Lopez, P. Papaldo, L. Lauro, 2004, Investigational New Drugs.

Phase II evaluation of oral idarubicin (4-demethoxydaunorubicin) in patients with disseminated malignant melanoma.

L. di Lauro, P. Papaldo, M. López, 1986, Cancer treatment reports.

Toxicity and activity of docetaxel in anthracycline-pretreated breast cancer patients: a phase II study.

M. Milella, F. Cognetti, D. Giannarelli, 2000, American journal of clinical oncology.

Improved prognosis by trastuzumab of women with HER2-positive breast cancer compared with those with HER2-negative disease.

A. Fabi, G. Ferretti, P. Papaldo, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Single-agent vinorelbine in pretreated breast cancer patients: comparison of two different schedules.

M. Milella, F. Cognetti, A. Fabi, 2004, Journal of experimental & clinical cancer research : CR.

Identification of the highest dose of docetaxel associable with active doses of epirubicin. Results from a dose-finding study in advanced breast cancer patients.

F. Cognetti, R. Rosso, M. Venturini, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy

F. Cognetti, A. Fabi, D. Giannarelli, 2012, BMC Cancer.

Epidermal growth factor receptor gene copy number may predict lapatinib sensitivity in HER2-positive metastatic breast cancer

M. Marino, M. Mottolese, F. Cognetti, 2013, Expert opinion on pharmacotherapy.

Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation

M. Mottolese, M. Milella, F. Cognetti, 2008, Cancer Chemotherapy and Pharmacology.

Phase II study of epirubicin in advanced malignant melanoma

C. Perno, Massimo Lopez, P. Papaldo, 2004, Investigational New Drugs.

Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide.

S. Di Cosimo, A. Fabi, P. Carlini, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Epirubicin plus docetaxel in metastatic breast cancer: escalating dose does not improve efficacy. A phase II study.

M. Pino, S. Di Cosimo, F. Cognetti, 2004, Anticancer research.

Pegylated liposomal doxorubicin in combination with gemcitabine: a phase II study in anthracycline-naïve and anthracycline pretreated metastatic breast cancer patients

M. Mottolese, F. Cognetti, A. Fabi, 2006, Cancer Chemotherapy and Pharmacology.

Chemotherapy in metastatic male breast cancer.

L. di Lauro, P. Papaldo, M. López, 1985, Oncology.

Colorectal cancer after breast cancer: a case-control study.

L. Sanchez-Mete, V. Stigliano, I. Sperduti, 2011, Cancer epidemiology.

Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials

M. Aapro, F. Puglisi, M. Milella, 2011, Journal of experimental & clinical cancer research : CR.

Lonidamine: efficacy and safety in clinical trials for the treatment of solid tumors.

Paolo Carlini, S. Di Cosimo, F. Cognetti, 2003, Drugs of today.

5-Fluorouracil, adriamycin, and BCNU (FAB) combination chemotherapy for advanced gastric cancer

Massimo Lopez, P. Papaldo, L. Lauro, 2004, Cancer Chemotherapy and Pharmacology.

5-Fluorouracil, adriamycin, and BCNU (FAB) combination for advanced gastric cancer

C. Perno, Massimo Lopez, P. Papaldo, 1984 .

Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients

M. Caterino, M. Mottolese, F. Cognetti, 2015, Drug design, development and therapy.

Mitomycin C in patients with metastatic breast cancer refractory to hormone therapy and chemotherapy.

C. Perno, L. di Lauro, P. Papaldo, 1983, Oncology.

Chemotherapy-induced amenorrhea in early breast cancer.

F. Cognetti, A. Fabi, P. Carlini, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Is anthracycline-based chemotherapy alone adequate for young women with estrogen receptor-positive breast cancer?

S. Di Cosimo, F. Cognetti, A. Fabi, 2006, Breast.

Activity of trastuzumab (t) beyond disease progression in HER2 over-expressing metastatic breast cancer (MBC)

S. Cosimo, M. Mottolese, F. Cognetti, 2007 .

A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease.

S. Cosimo, M. Pino, M. Mottolese, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

5-Fluorouracil, Adriamycin and Cyclophosphamide Combined with High-Dose Medroxyprogesterone Acetate in Advanced Breast Cancer

C. Perno, L. di Lauro, Massimo Lopez, 1983, Tumori.

Liver toxicity after treatment with gefitinib and anastrozole: drug-drug interactions through cytochrome p450?

M. Milella, F. Cognetti, A. Fabi, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Breast cancer and timing of surgery during menstrual cycle: a 5‐year analysis of 248 premenopausal women

M. Milella, F. Cognetti, A. Fabi, 1999, Breast Cancer Research and Treatment.

Sequential epirubicin-docetaxel-CMF as adjuvant therapy of early breast cancer: Results of the Taxit216 multicenter phase III trial.

C. Boni, S. Palazzo, F. Cognetti, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer.

S. Cosimo, M. Mandalà, S. Di Cosimo, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Time to First Tumor Progression as Outcome Predictor of a Second Trasuzumab‐Based Therapy beyond Progression in HER‐2 Positive Metastatic Breast Cancer 1

M. Mottolese, F. Cognetti, A. Fabi, 2010, The breast journal.

Controlled study of DTIC versus DTIC plus epirubicin in metastatic malignant melanoma

C. Perno, Massimo Lopez, P. Papaldo, 2004, Investigational New Drugs.

Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials

S. Cosimo, S. Di Cosimo, M. Milella, 2006, British Journal of Cancer.

Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial

S. Barni, C. Boni, P. Bruzzi, 2015, The Lancet.

Does the concurrent use of anthracycline and granulocyte colony-stimulating factor influence the risk of secondary leukaemia in breast cancer women?

S. Di Cosimo, A. Alimonti, F. Cognetti, 2005, Annals of Oncology.